Approximately 0Á2-1% of routine RhD blood typings result in a "serological weak D phenotype." For more than 50 years, serological weak D phenotypes have been managed by policies to protect RhD-negative women of child-bearing potential from exposure to weak D antigens. 
Since the identification of the Rh factor more than 7 decades ago (Levine & Stetson, 1939; Landsteiner & Weiner, 1940) , recipients of blood transfusions and blood donors have been categorized as either RhD-positive [D+ red blood cells (RBCs)] or RhD-negative (DÀ) RBCs. In 1946, the first D variant antigen was reported, that is, RBCs that did not agglutinate when RhD typed by certain anti-D sera, but did agglutinate when typed with other anti-D sera (Stratton, 1946) . Stratton named these D variants D U . Subsequently, case reports revealed that some women with a D U phenotype who had been exposed to D+ RBCs by transfusion or pregnancy formed anti-D (Argall et al, 1953; Simmons & Krieger, 1960; Ostgard et al, 1986; Mayne et al, 1991; Domen & Hoetge, 1997) . Additional pregnancies were reported that were complicated by RhD haemolytic disease of the fetus and newborn (Hill et al, 1974; Lacey et al, 1983; White et al, 1983; Cannon et al, 2003 
Clinical importance of the RhD blood group antigen
From a clinical perspective, the Rh blood group system is the most important of the 36 blood group systems (Storry et al, 2016) after ABO. Among the 54 blood group antigens in the Rh system, the RhD antigen is the most immunogenic and important in clinical practice (Gunson et al, 1976; Urbaniak & Robertson, 1981; Storry et al, 2014) . The consequence of an RhD-negative woman forming anti-D is that any subsequent pregnancy involving an RhD-positive fetus is at risk for morbidity and mortality associated with Rh haemolytic disease of the fetus and newborn. The consequence of any RhD-negative individual forming anti-D is that the option of transfusing D+ RBCs in an emergency is eliminated and there is now an absolute lifetime requirement for transfusing only DÀ RBCs.
Report of the first D variant antigen (D U ) and subsequent changes in terminology Stratton (1946) reported that RBCs from a blood donor at the Manchester Royal Infirmary failed to agglutinate with 20 anti-D sera, but agglutinated variably with 12 other anti-D sera. Stratton determined that the donor had inherited a D variant antigen from his father, as did his two brothers. He reported the D variant as a "new Rh allelomorph" and named it "D U ." As more sensitive RhD typing methods were developed, it became apparent that an individual's RBCs that typed as D U by a relatively insensitive manual tube method may be typed as a straightforward D+ (RhD-positive) if retested by a potent monoclonal anti-D reagent, or by a more sensitive manual or an automated RhD typing method (Agre et al, 1992) .
In 1992, Ortho Diagnostics (Raritan, NJ) convened a meeting of immunohaematologists to consider the impact of these more sensitive RhD typing methods on the terminology for D for all weak expressions of the D antigen [to] eliminate much of the confusion caused by inconsistent and sometimes erroneous terminology" (Agre et al, 1992) . Within a decade, new laboratory methods were developed capable of determining RHD genotypes that were expressed as a serological weak D phenotype (Flegel et al, 1998; Wagner et al, 1999) . Molecular scientists began to report RHD genotypes as "weak D type 1," "weak D type 2," and so forth, introducing terminology for RHD genotyping that could be confused easily with the "weak D" designation intended by Agre et al (1992) for serologically-determined weak expression of the D antigen.
In 2015, the AABB (formerly, American Association of Blood Banks) and the College of American Pathologists (CAP) convened a Work Group on RHD Genotyping and charged it with developing recommendations to clarify clinical issues related to RhD typing (Sandler et al, 2015) . The Work Group published its recommendations using the term "serologic weak D phenotype" to distinguish the result of serological weak D testing using anti-human globulin in clinical laboratories versus the results of RHD genotyping for weak D types based on molecular methods.
A laboratory report of a serological weak D phenotype reflects sensitivity of the laboratory's method, as well as the molecular basis for the weak D antigen
In the United States, a serological weak D phenotype is usually defined as reactivity of RBCs with an anti-D reagent giving no or weak (≤2+) reactivity in initial testing, but agglutinating moderately or strongly with anti-human globulin (a weak D test) (Jenkins et al, 2005; Daniels, 2013; Sandler et al, 2015) . In Europe, such a "weak D test" is often understood to be what a reference laboratory does to resolve equivocal serological reactivity, whether by serological or molecular methods. Grading a serological reaction as ≤2+ is often subjective and there is a lack of consensus for the definition. In the UK and Ireland, most clinical laboratories use potent anti-D reagents and few use indirect antiglobulinreactive anti-D reagents. Any serological reaction of ≤2+ is likely to be referred to a Red Cell Immunohaematology (RCI) Laboratory. Typically, RCI Laboratories use the Quotient Advanced Partial RhD Typing Kit (Quotient/Alba Bioscience Limited, Edinburgh, Scotland), comprising of 12 9 IgG anti-D reagents, to identify serological weak D phenotypes. RCI Laboratories in the UK do not currently perform RHD genotyping for these patients' samples. In Ireland, RHD genotyping for serological weak D phenotypes commenced in 2016. The observed prevalence of serological weak D phenotypes increases when the laboratory method of detection is relatively insensitive, for example, manual tube testing. In this situation, the first phase of anti-D detection may be too insensitive to agglutinate RBCs with a D variant antigen, but the RBCs will be agglutinated by the second weak D test phase and, therefore, the sample is interpreted to be a serological weak D phenotype. In contrast, the observed prevalence of serological weak D phenotypes decreases when the method of detection is more sensitive, for example, an automated gel column or solid-phase analyser using a blend of potent recombinant monoclonal anti-D reagents. In this situation, the highly sensitive first phase of D antigen testing by anti-D will agglutinate RBCs expressing a weak D antigen and the sample is interpreted to be a conventional RhD-positive. Thus, a blood sample from a patient or blood donor with a weak D variant antigen may be interpreted to be RhD-positive when tested by a laboratory using (Table I ). An estimated 0Á2-1Á0% of Caucasians inherit an RHD genotype that codes for a serological weak D phenotype (Garratty, 2005) . In North London, the prevalence of weak D phenotypes was estimated to be 0Á3% for white and 1Á7% for black blood donors (Contreras & Knight, 1991) .
A serological weak D phenotype is the expression of an amino acid substitution in the RhD protein or an RHD-RHCE-D gene conversion causing a D variant antigen
The molecular basis for a serological weak D phenotype can be determined by retesting the blood sample by one of several molecular methods to identify the underlying mutation or recombination (Monteiro et al, 2011; Tilley & Grimsley, 2014) . The most common D variant antigen identified when a serological weak D phenotype is detected in a Caucasian is a molecularly defined weak D type. Less commonly, a serological weak D phenotype is associated with a partial D phenotype, which is a D variant most frequently expressed as D+, but may occasionally present as a serological weak D phenotype. A third category of D variants, DEL phenotypes, is included in this review for the purpose of a comprehensive overview of D variants, but the expression of the D antigen in DEL phenotypes is too weak to be detected as a serological weak D phenotype. Molecular studies of D antigens in different populations reveal a significant number of D variant alleles among individuals who type as RhD-negative by routine serological methods. A study of 33 864 hospital patients in Toronto, Canada revealed that at least 0Á96% of RhD-negative patients expressed an RHD variant allele (Denomme et al, 2005) . A study of 37 782 RhD-negative pregnant Dutch women detected 0Á96% with a D variant allele (Stegmann et al, 2016) . The prevalences of RHD alleles in studies conducted among RhD-negative donors in Europe, East Asia, South America and North Africa are summarized in a review (Denomme, 2013) .
Weak D types
A molecularly defined weak D type is a variant of the RhD protein with an amino acid substitution in the trans-membranous or intracellular segment and expresses a decreased quantity of D antigen (Wagner et al, 1999; Flegel et al, 2007) (Fig 1) . Most serological weak D phenotypes (>95% in Northern Europeans) are the expression of weak D types 1, 2, 3 or 4Á0/4Á1 (Flegel, 2011) . To date, 147 weak D types have been listed on the Rhesus database (http://www.rhesusbase. info/) (Table II) .
Partial D phenotypes
Partial D phenotypes were initially described as "blood factors" (Unger et al, 1959) , then as "mosaics" (Tippett & Sanger, 1962; Weiner & Unger, 1962) . Salmon et al (1984) introduced the term "partial D" (Issitt & Telen,1996) . Molecular studies have determined that RBCs expressing a partial D phenotype have an amino acid substitution in at least one of the extracellular or RBC membrane surface loops (Wagner et al, 1999; Flegel et al, 2007) (Fig 1) . Most RBCs express a partial D phenotype as D+ by routine serological methods and are not detected as serological weak D phenotypes. They are not detected by routine RhD typing unless the individual has been exposed to D+ RBCs and formed anti-D (Westhoff, 2005) . Occasionally, partial D RBCs have decreased expression of the D antigen and are detected as a serological weak D phenotype by routine RhD typing (Westhoff, 2005; Stegmann et al, 2016) . Approximately 5-10% of weak D phenotypes in the United States are estimated to be partial D phenotypes (Garratty, 2005) . There are 105 partial D types listed by the Rhesus database (http://www.rhesusbase.info/). Partial D types are also separated into D categories, of which DVI is the most common and most likely to be associated with formation of anti-D in Caucasian populations. The prevalence of DVI in South-western Germany among more than 70 000 blood donors was 0Á02% (Wagner et al, 1995) . In South-western England, 5Á0% of blood donors classified as D U were found to have the category DVI phenotype (Leader et al, 1990) . In the United States, monoclonal anti-D blood typing reagents are selected to avoid detection of DVI RBCs (Wagner et al, 1995; Judd et al, 2005 (Okubo et al, 1984 (Okubo et al, , 1991 Yasuda et al, 2005; Kim et al, 2009; Shao, 2010; Yang et al, 2015) . Transfusion recipients with a complete DEL phenotype and an RHD (1227G>A) allele (Asian-type DEL) are not at risk of forming anti-D following transfusion of D+ RBCs . Pregnant women with a complete DEL phenotype who deliver an RhD-positive newborn are not at risk for forming anti-D, but pregnant women with certain partial or hybrid DEL alleles are at risk for forming anti-D. There are significant differences in the prevalence of DEL phenotypes and the (Yang et al, 2007; Gu et al, 2014) and of these, as many as 30% express the DEL phenotype (Shao et al, 2002; Wagner et al, 2005) . In Japanese, 0Á5% are RhD-negative (Okubo et al, 1991) and 28% of these express a DEL phenotype (Fukumori et al, 1997) . In Koreans, 0Á15% are RhD-negative and of these, 17% express a DEL phenotype (Kim et al, 2005; Luettringhaus et al, 2006) . The prevalence of DEL phenotypes is significantly less in Caucasians, of whom approximately 15% are RhD-negative and only 0Á1% of these express a DEL phenotype (Flegel et al, 2009 ). Among the 3-5% of African Americans who are RhD-negative, there are no reports of DEL phenotypes (Daniels, 2002) .
When are serological weak D phenotypes detected?
Most serological weak D phenotypes are detected when a pregnant woman, potential transfusion recipient or blood donor has a blood sample routinely typed for RhD and the grade of RBC agglutination is weaker (≤2+) than expected for RhD typing using potent anti-D reagents (3+ to 4+). Also, serological weak D phenotypes are detected when a clinical laboratory types a blood sample as D+, but the laboratory's record of a prior RhD type is DÀ. The discrepancy may reflect an error in patient or sample identification. Alternatively, the discrepancy may reflect the increased potency of new monoclonal RhD typing reagents in the laboratory compared to previously used plasma-derived anti-D reagents that were less effective for detecting weakly expressed D variant antigens.
Applying RHD genotyping results in clinical practice
In the United States, the longstanding laboratory practice of not performing a weak D test for transfusion recipients and pregnant women -and/or managing serological weak D phenotypes as RhD-negative -has proven to be a safe strategy in that it protects susceptible individuals from RhD alloimmunization and forming anti-D. However, that practice results in unnecessary transfusion of difficult-to-obtain DRBCs for many transfusion recipients and unnecessary injections of Rh immune globulin for many pregnant women (Sandler et al, 2015) . The following section describes how RHD genotyping transfusion recipients with a serological weak D phenotype can conserve inventories of RhD-negative RBCs without compromising transfusion safety. Also, RHD genotyping pregnant women when a serological weak D is detected can avoid unnecessary injections of Rh immune globulin without compromising the safety of their pregnancy or the fetus.
Blood donors and transfusion recipients
Following recognition that RhD haemolytic disease of the fetus and newborn was the result of RhD-negative mothers forming anti-D, clinical practice guidelines required that (Ooley, 2015) . In contrast, the current 30th edition of Standards considers a weak D test for transfusion recipients to be "optional," resulting in most recipients with a serological weak D phenotype being categorized as RhD-negative, protecting them from inadvertent exposure to RBCs that are either D+ or express a serological weak D phenotype (Ooley, 2015) . In 2014, CAP conducted a survey of policies and practices for testing serological weak D phenotypes and administration of Rh immune globulin involving more than 3100 laboratories in the United States (Sandler et al, 2014a) . This survey revealed that there was a lack of standard practice for interpreting the RhD type when a serological weak D phenotype was detected. Observational studies in central Europe indicate that transfusion recipients with a weak D type 1, 2 or 3 in the homozygous or hemizygous state are not at risk for forming alloanti-D when exposed to D+ RBCs (Wagner et al, 2000; Flegel, 2006) . Approximately 90% of Caucasians in central Europe with a serological weak D phenotype have a weak D type 1, 2 or 3 and can be managed safely as RhDpositive (Flegel, 2007) . The AABB-CAP Work Group recommended that RHD genotyping be performed for transfusion recipients when a serological weak D phenotype is detected by routine RhD typing. Those patients whose serological weak D phenotype is associated with a molecularly defined weak D type 1, 2 or 3 may be transfused safely with D+ RBCs (Fig 2) . Although an automated DNA extraction system can extract DNA from whole blood in less than one hour, turnaround times increase if the laboratory uses manual methods for the extraction. Currently, in the United States, most RHD genotyping is performed in reference laboratories and, therefore, the turnaround time is more than 1 day, excluding the procedure for patients requiring an urgent transfusion. For patients requiring chronic transfusions, for example, sickle cell disease, thalassaemia and myelodysplastic syndrome, the results of once-in-a-lifetime RHD genotyping may not be available in time for the current transfusion, but would be available for future transfusions (Chou et al, 2013; Fasano & Chou, 2016 to minutes, making RHD genotyping feasible for real-time application in the hospital (Wagner et al, 2017) . Patients with sickle cell disease benefit from RHD genotyping, not only because most have a requirement for chronic transfusion, but also because they are at increased risk of alloimmunization to certain Rh and other blood group antigens because of the differences that they inherit from their African ancestry compared to those inherited by the predominately Caucasian donors in Western countries (Vichinsky et al, 1990) .
Pregnant women
In the United States, guidelines for managing pregnant women with a serological weak D phenotype were first introduced in 1981 (Oberman, 1981) . The American Association of Blood Banks issued a standard that a woman's candidacy for Rh immune globulin should be determined by the same laboratory method as that for RhD typing of blood donors (Oberman, 1981) . Thus, women with a serological weak D phenotype were categorized as RhD-positive and not considered candidates for Rh immunoprophylaxis with Rh immune globulin. Within a few years, there were reports of women with a serological weak D who delivered an RhD-positive newborn, did not receive Rh immune globulin, and who formed anti-D (White et al, 1983; Ostgard et al, 1986; Mayne et al, 1991; Domen & Hoetge, 1997) . Currently, in the UK and Ireland, women with a serological weak D phenotype are often managed as RhD-positive. Although most of these women would be determined to be RhD-positive if RHD genotyped, a minority will have an RHD type other than 1, 2 or 3 that would qualify them as candidates for Rh immune globulin. The AABB standard was revised in the current 30th edition of AABB's Standards which determines a pregnant woman's candidacy for Rh immune globulin using the same RhD typing method for as that for a transfusion recipient, that is, the woman's anti-D typing of RBCs is negative and the test for weak D is optional (Ooley, 2015) . A survey of hospital practice in the United States by CAP in 2014 revealed that only 19Á8% of responding laboratories performed a weak D test when a patient's RBCs typed negative by the initial anti-D test (Sandler et al, 2014a) . Thus, most pregnant women in the United States with a serological weak D phenotype are managed without a weak D test as RhDnegative for purposes of Rh immunoprophylaxis with Rh immune globulin. While this strategy is safe and prevents Rh alloimmunization of RhD-negative pregnant women, the practice results in many pregnant women receiving unnecessary injections of Rh immune globulin. The AABB-CAP Work Group reviewed data pertaining to the safety of managing pregnant women and women of childbearing potential with a serological weak D phenotype. The Work Group determined that pregnant women with a weak D type 1, 2 or 3 in the homozygous or hemizygous state are not at risk of forming alloanti-D when exposed to conventional D+ RBCs (Sandler et al, 2015) . The Work Group recommended that RHD genotyping be performed when routine RhD typing resulted in a serological weak D phenotype for a pregnant women or a woman of childbearing potential. If the result was a weak D type 1, 2 or 3, the woman can be managed safely as RhD-positive, because she is not at risk of forming anti-D (Fig 2) Cost effectiveness of RHD genotyping pregnant women with a serological weak D phenotype A study using a Markov-based model evaluated the costs of options for managing the administration of Rh immune globulin in pregnant women in the United States whose RhD type was reported to be a serological weak D phenotype (Kacker et al, 2015) . The study determined that there would be cost saving when the cost of RHD genotyping was less than 256 USD. Genotyping would decrease net cost among non-Hispanic Caucasian females, but would increase cost among nonHispanic African Americans, non-Hispanic American Indian/ Alaskans and Hispanic women (Kacker et al, 2015) . The differences in cost for RHD genotyping different populations are a reflection of the higher prevalence of serological weak D phenotypes associated with weak D types 1, 2 or 3 in Caucasians compared to other racial and ethnic populations.
It's time for a paradigm shift: Clinical laboratories should implement policies to increase detection of serological weak D phenotypes and resolve their interpretation by RHD genotyping, not avoid their detection or make detection optional Prior to the availability of molecular methods capable of distinguishing different D variant antigens that are expressed as serological weak D phenotypes, laboratory practice in the United States was avoidance of the issue. Serological weak D phenotypes were interpreted as RhD-negative for pregnant women and transfusion recipients, and as RhD-positive for blood donors (Sandler et al, 2014a) . For the past 50 years, laboratories have used RhD typing policies and procedures selected for their avoidance of detecting D variant antigens. It's time to change the paradigm and select RhD typing reagents that will not only detect normal ("wild type") RhD antigens, but also detect D variant antigens. Such a scenario has been proposed and is feasible by RhD typing using two monoclonal anti-D reagents, one recognizing DVI and other clinically important partial D variants, and another not recognizing clinically important partial D variants. (Denomme et al, 2005; Garratty, 2005; Denomme & Flegel, 2008; Von Zabern et al, 2013) . Discrepant results using the two-reagent protocol would prompt identification of the variant D allele by molecular methods.
Laboratories and transfusion services should discontinue reporting "serological weak D phenotype" as a test result in response to a request to perform an RhD blood type Traditionally, clinical practice for Rh immunoprophylaxis with Rh immune globulin, as well as transfusion of RBCs, has been based on interpreting the results of RhD typing as RhD-positive or RhD-negative. Advances in molecular science have identified 147 weak D alleles of the RHD gene, but the longstanding practice of managing pregnant women and patients as either RhD-positive or RhD-negative continues to be safe and adequate. As the science of RhD typing increasingly relies on RHD genotyping to guide the interpretation of serological weak D phenotypes, molecular laboratories have the responsibility of providing reports that are readily interpreted for managing patients as either RhD-positive or RhD-negative. It's time for laboratories to discontinue the practice of reporting "serological weak D phenotype" in response to a request to perform an RhD type. Today, given the laboratory resources for resolving a serological weak D phenotype, a laboratory offering RhD typing for clinical services should have an internal procedure for resolving the occasional serological weak D result by "reflexively" (automatically) performing RHD genotyping or referring the blood sample to a molecular reference laboratory for resolution.
Should in-hospital clinical laboratories or regional reference laboratories perform the molecular testing required to resolve serological weak D phenotypes?
Many models exist that demonstrate the cost savings and opportunities for increased quality when low volume tests are centralized in a reference laboratory. As clinicians increasingly recognize the benefit of applying RHD genotyping to resolve serological weak D phenotype results, laboratories will have options for providing the new service. Adding an in-hospital molecular service for blood groups will require the purchase of an automated extractor for DNA, PCR work stations, centrifuges, a thermal cycler, hybridization oven, imaging system and a computer (Sapatnekar & Figueroa, 2014) . The initial capital expense and the ongoing cost of maintaining technical expertise for a relatively low-volume service are not realistic for most hospitals. For hospitals, an alternative model, i.e., centralizing the required molecular services in a community-based regional blood group reference laboratory, is more realistic. In our opinion, the second option -hospitals refer blood samples for RHD genotyping to reference laboratories -has the advantages of cost-effective high-volume operations which can fund highly skilled molecular scientists and acquire upto-date technology (analysers) as this new laboratory science evolves (Hillyer et al, 2008; Sandler et al, 2014b) .
